BioCentury
ARTICLE | Clinical News

Boehringer's idarucizumab meets in Phase III

June 23, 2015 1:38 AM UTC

Boehringer Ingelheim GmbH (Ingelheim, Germany) reported interim data from the Phase III RE-VERSE AD trial of idarucizumab to reverse the anticoagulant effects of Pradaxa dabigatran etexilate in patients who have uncontrolled bleeding or require emergency surgery or procedures. Data were presented at the International Society of Thrombosis and Haemostasis Congress in Toronto, and were published in The New England Journal of Medicine.

The trial met its primary endpoint of maximum reversal of anticoagulant effect within four hours as measured by ecarin clotting time (ECT) or diluted thrombin time (dTT). ...